Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

asciminib 15Cyclophosphamide 12fludarabine phosphate 10Mycophenolic Acid 9fludarabine 8nilotinib 7Whole-Body Irradiation 7Imatinib Mesylate 6Dasatinib 6Tacrolimus 5Sirolimus 5Cyclosporine 5venetoclax 4bosutinib 4Melphalan 4Granulocyte Colony-Stimulating Factor 4ponatinib 3Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Cyclosporins 3Busulfan 3thymoglobulin 2ruxolitinib 2Specimen Handling 2Mesna 2Magnetic Resonance Spectroscopy 2Filgrastim 2Blood Component Removal 2treosulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × midostaurin × 90 days × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡